A Phase 1/2 interventional study of cabazitaxel and gemcitabine in Neoplasms, Malignant, sponsored by Sanofi. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-11.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objectives:
Secondary Objectives:
For study part 1, dose levels were to be escalated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT during the first 3 weeks of treatment. There was no further dose escalation when this dose was achieved. The MTD was defined as the highest dose at which 0 or 1 of 3 to 6 patients, respectively, experienced DLT during the first 3 weeks of treatment.
The study consisted of a screening phase (maximum length of 21-day), a treatment phase with 21-day treatment cycles and a 30-day follow-up visit after the last dose of study medication.
The cut-off date for study part 1 was when last participant completed the first treatment cycle and the subsequent 30 days follow-up.
The cut off date for study part 2 was when all participants experienced disease progression, unacceptable toxicity, consent withdrawal or the last participant had completed 26 weeks or 6 cycles on study treatment, whichever came first.
Participants could continue to be treated on study as long as they were benefiting from study treatment and had not met study withdrawal criteria. After withdrawal from study treatment, further treatment, if any, was at the discretion of the Investigator.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 19 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision. On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel.
Drug: cabazitaxel · Drug: gemcitabine
Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion Route of administration: Intravenous infusion over 60 minutes Dosage: * Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule * Study part 2: MTD as determined in Study part 1
Also known as: XRP6258, Jevtana
Pharmaceutical form: According to United States Package Insert (USPI) Route of administration: Intravenous infusion over 30 minutes Dosage: * Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule * Study part 2: MTD as determined in Study part 1.
Also known as: Gemzar
Participants With Dose Limiting Toxicities During Dose Escalation
Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).
Time frame: Day 1 to Day 21 of the first treatment cycle
Objective Response Rate With MTD
Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion. The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
Time frame: Fron Day 1 up to a maximum of 12 months
Time To Progression With MTD
Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (\>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions). Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
Time frame: Fron Day 1 up to a maximum of 12 months
Duration of Response With MTD
Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death. Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
Time frame: Fron Day 1 up to a maximum of 12 months
Participants With Adverse Events
Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE. Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased. NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.
Time frame: from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)
Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)
Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL. Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)
Area under the plasma concentration versus time curve extrapolated to infinity
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)
Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion; * Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)
Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion; * Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)
Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)
Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC
Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.
Time frame: Day 1 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion) and Day 8 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion)
Participants were enrolled in 4 sites in the United States. Since it was not possible to determine the maximum Tolerated Dose (MTD) in study part 1, no participant was enrolled in study part 2 and the study was stopped.
| Milestone | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Part 2: Cabazitaxel + Gemcitabine MTD |
|---|---|---|---|---|---|
| Started | 5 | 5 | 3 | 6 | 0 |
| Treated | 5 | 5 | 2 | 6 | 0 |
| Completed 1st treatment cycle | 5 | 5 | 2 | 6 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 5 | 3 | 6 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 2 | 0 |
| Withdrew: Disease progression | 3 | 2 | 2 | 4 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Not treated; protocol exclusion | 0 | 0 | 1 | 0 | 0 |
Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).
| participants | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Participants With Dose Limiting Toxicities During Dose Escalation | 2 | 2 | 2 | 2 |
Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (\>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions). Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
No measurements were reported for this outcome.
Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death. Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
No measurements were reported for this outcome.
Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE. Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased. NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.
| participants | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Any AE | 5 | 5 | 2 | 6 |
| Any TEAE | 5 | 5 | 2 | 6 |
| - Drug-related TEAE | 5 | 5 | 2 | 6 |
| Grade 3-4 TEAE | 5 | 5 | 2 | 6 |
| - Grade 3-4 drug-related TEAE | 4 | 5 | 2 | 6 |
| Serious TEAE | 5 | 2 | 2 | 4 |
| - Drug-related serious TEAE | 3 | 2 | 2 | 3 |
| AE leading to drug withdrawn | 2 | 2 | 0 | 2 |
| - Drug-related AE leading to drug withdrawn | 0 | 2 | 0 | 1 |
| AE leading to death | 1 | 0 | 0 | 0 |
| AE leading to dose reduction | 3 | 4 | 2 | 4 |
| AE leading to dose delay | 4 | 2 | 1 | 4 |
Participant Best response was assessed by investigator using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1: * Complete response (CR): Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm: * Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion; * Progressive disease (PD): \>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions; * Stable disease (SD): not a CR, PR or PD.
| participants | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 0 |
| Partial response | 1 | 1 | 0 | 1 |
| Stable disease | 2 | 3 | 0 | 3 |
| Progressive disease | 1 | 1 | 2 | 2 |
| Not evaluable | 1 | 0 | 0 | 0 |
Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL. Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.
| ng/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax) | 123 ± 43.7 | 150 ± 80.9 | 273 ± 21.9 | 118 ± 43.9 |
| hours (hr) | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax) | 1.00 (0.92 to 1.05) | 0.94 (0.87 to 0.95) | 0.94 (0.88 to 1.00) | 0.93 (0.92 to 1.03) |
Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast) | 556 ± 500 | 352 ± 101 | 344 ± 114 | 315 ± 208 |
Area under the plasma concentration versus time curve extrapolated to infinity
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC) | 876 ± 730 | 420 ± 77.3 | 462 ± 156 | 306 ± 50.1 |
| hours (hr) | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z) | 92.1 ± 40.3 | 88.3 ± 35.1 | 75.6 ± 27.8 | 70.3 ± 43.1 |
| L/hr | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL) | 61.0 ± 38.4 | 64.3 ± 16.2 | 59.5 ± 6.38 | 90.8 ± 7.15 |
| L | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss) | 6780 ± 3250 | 4980 ± 818 | 3930 ± 1170 | 5570 ± 2100 |
| L/hr/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA) | 32.4 ± 18.3 | 36.1 ± 6.58 | 31.9 ± 12.6 | 49.6 ± 8.56 |
| L/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA) | 3530 ± 1650 | 2690 ± 434 | 1980 ± 8.83 | 3020 ± 1130 |
Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion; * Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
| ng/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax) | 14600 ± 6050 | 35600 ± 27200 | 11400 ± 3270 | 19000 ± 9130 |
| hours (hr) | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax) | 0.49 (0.47 to 0.50) | 0.38 (0.37 to 0.55) | 0.60 (0.53 to 0.67) | 0.42 (0.37 to 0.50) |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast) | 7320 ± 1650 | 16000 ± 11100 | 6120 ± 3350 | 9920 ± 5290 |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC) | 6290 ± 1440 | 21900 ± 10800 | 8530 ± NA | 9970 ± 5310 |
| hours | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z) | 0.295 ± 0.118 | 0.254 ± 0.0570 | 0.202 ± NA | 0.256 ± 0.0933 |
| L/hr | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL) | 313 ± 120 | 85.1 ± 40.6 | 123 ± NA | 174 ± 106 |
| L | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss) | 135 ± 86.2 | 28.9 ± 30.4 | 47.0 ± NA | 51.6 ± 28.8 |
| L/hr/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA) | 159 ± 31.3 | 49.8 ± 27.0 | 78.4 ± NA | 96.4 ± 62.8 |
| L/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA) | 66.5 ± 31.7 | 17.3 ± 18.9 | 29.9 ± NA | 28.7 ± 17.4 |
Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion; * Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
| ng/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax) | 10200 ± 283 | 34500 ± 30800 | — | 14100 ± 12200 |
| hours (hr) | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax) | 0.52 (0.52 to 0.52) | 0.45 (0.42 to 0.55) | — | 0.47 (0.40 to 0.48) |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast) | 5530 ± 1150 | 15300 ± 11900 | — | 7710 ± 6840 |
| hours (hr) | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z) | 0.222 ± NA | 0.282 ± 0.0218 | — | 0.317 ± 0.113 |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC) | 6360 ± NA | 18500 ± 12300 | — | 7780 ± 6880 |
| L/hr | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL) | 262 ± NA | 110 ± 55.8 | — | 252 ± 158 |
| L | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss) | 104 ± NA | 36.2 ± 19.4 | — | 93.3 ± 51.7 |
| L/hr/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA) | 157 ± NA | 62.8 ± 32.7 | — | 143 ± 93.3 |
| L/m^2 | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA) | 62.2 ± NA | 20.6 ± 11.6 | — | 52.3 ± 28.6 |
Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
| ng/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax) | 32200 ± 10000 | 32500 ± 10800 | 25500 ± 8770 | 21100 ± 5980 |
| hours | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax) | 0.73 (0.50 to 0.77) | 0.77 (0.47 to 0.83) | 0.65 (0.53 to 0.77) | 0.77 (0.50 to 1.47) |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast) | 227000 ± 27500 | 235000 ± 47400 | 167000 ± 47500 | 168000 ± 57000 |
| hours | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z) | 9.07 ± 2.22 | 9.41 ± 0.837 | 7.96 ± 1.87 | 12.1 ± 5.17 |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC) | 273000 ± 58100 | 285000 ± 61200 | 191000 ± 66900 | 151000 ± 37700 |
Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.
| ng/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax) | 27400 ± 3180 | 34800 ± 8630 | — | 18700 ± 4740 |
| hours | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax) | 0.69 (0.52 to 0.85) | 0.68 (0.55 to 1.02) | — | 0.72 (0.70 to 1.00) |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast) | 216000 ± 3700 | 287000 ± 77500 | — | 141000 ± 26400 |
| hours | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z) | 7.29 ± 1.11 | 8.55 ± 0.820 | — | 9.10 ± 0.484 |
| ng*hr/ml | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC) | 240000 ± 11300 | 340000 ± 100000 | — | 168000 ± 27600 |
Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.
| ratio | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| AUClast | 1.15 (NA to NA) | 1.17 (0.661 to 2.49) | — | 1.11 (0.994 to 1.25) |
| AUC | 1.15 (NA to NA) | 1.24 (0.660 to 2.47) | — | 1.11 (0.994 to 1.25) |
Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion. The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.
No measurements were reported for this outcome.
Collected over from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabazitaxel + Gemcitabine Dose Level 0 | — | 5/5 (100%) | 5/5 (100%) |
| Cabazitaxel + Gemcitabine Dose Level -1 | — | 2/5 (40%) | 5/5 (100%) |
| Cabazitaxel + Gemcitabine Dose Level -2 | — | 2/2 (100%) | 2/2 (100%) |
| Gemcitabine + Cabazitaxel Dose Level 0 | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/5 | 0/5 | 2/2 | 1/6 |
| PneumoniaInfections and infestations | 0/5 | 0/5 | 1/2 | 0/6 |
| SepsisInfections and infestations | 0/5 | 0/5 | 1/2 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/5 | 0/5 | 1/2 | 1/6 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 0/5 | 0/2 | 0/6 |
| NeutropeniaBlood and lymphatic system disorders | 1/5 | 1/5 | 0/2 | 0/6 |
| PancytopeniaBlood and lymphatic system disorders | 1/5 | 0/5 | 0/2 | 1/6 |
| LeukopeniaBlood and lymphatic system disorders | 0/5 | 1/5 | 0/2 | 0/6 |
| Supraventricular tachycardiaCardiac disorders | 1/5 | 0/5 | 0/2 | 0/6 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/5 | 0/5 | 0/2 | 0/6 |
| Event | Cabazitaxel + Gemcitabine Dose Level 0 | Cabazitaxel + Gemcitabine Dose Level -1 | Cabazitaxel + Gemcitabine Dose Level -2 | Gemcitabine + Cabazitaxel Dose Level 0 |
|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/5 | 1/5 | 2/2 | 0/6 |
| FatigueGeneral disorders | 2/5 | 4/5 | 1/2 | 5/6 |
| NeutropeniaBlood and lymphatic system disorders | 4/5 | 3/5 | 1/2 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 2/5 | 4/5 | 0/2 | 2/6 |
| NauseaGastrointestinal disorders | 1/5 | 4/5 | 0/2 | 2/6 |
| AnaemiaBlood and lymphatic system disorders | 0/5 | 1/5 | 0/2 | 4/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/5 | 3/5 | 0/2 | 4/6 |
| Weight decreasedInvestigations | 3/5 | 1/5 | 1/2 | 1/6 |
| Urinary tract infectionInfections and infestations | 0/5 | 1/5 | 1/2 | 0/6 |
| Viral upper respiratory tract infectionInfections and infestations | 0/5 | 0/5 | 1/2 | 0/6 |
| Age Continuous(years) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Mean | 60.8 ± 6.6 | 59.2 ± 9.2 | 53.0 ± 14.8 | 56.3 ± 16.1 | 57.7 ± 11.5 |
| Sex: Female, Male(Participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 3 | 8 |
| Male | 3 | 3 | 2 | 3 | 11 |
| Race/Ethnicity, Customized(participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Asian/Oriental | 0 | 0 | 1 | 0 | 1 |
| Black | 0 | 1 | 0 | 0 | 1 |
| Caucasian/White | 4 | 4 | 2 | 6 | 16 |
| Other | 1 | 0 | 0 | 0 | 1 |
| Body Surface Area(m^2) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Mean | 1.87 ± 0.32 | 1.82 ± 0.21 | 1.98 ± 0.42 | 1.84 ± 0.12 | 1.87 ± 0.24 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| 0 | 0 | 2 | 1 | 1 | 4 |
| 1 | 5 | 3 | 2 | 5 | 15 |
| 2 | 0 | 0 | 0 | 0 | 0 |
| Primary Tumor Site(participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Bladder | 0 | 0 | 1 | 1 | 2 |
| Colon | 0 | 1 | 0 | 0 | 1 |
| Head/neck | 0 | 1 | 1 | 0 | 2 |
| Lung | 2 | 1 | 1 | 0 | 4 |
| Muscle/soft tissue | 0 | 0 | 0 | 1 | 1 |
| Other | 0 | 1 | 0 | 0 | 1 |
| Ovaries | 0 | 0 | 0 | 1 | 1 |
| Pancreas | 1 | 1 | 0 | 1 | 3 |
| Pelvis | 0 | 0 | 0 | 1 | 1 |
| Prostate | 2 | 0 | 0 | 0 | 2 |
| Skin | 0 | 0 | 0 | 1 | 1 |
| Histological Type(participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Adenocarcinoma | 2 | 4 | 0 | 2 | 8 |
| Squamous cell carcinoma | 0 | 1 | 0 | 0 | 1 |
| Other | 3 | 0 | 3 | 4 | 10 |
| Stage at Diagnosis(participants) | Part 1: Cabazitaxel + Gemcitabine Dose Level 0 | Part 1: Cabazitaxel + Gemcitabine Dose Level -1 | Part 1: Cabazitaxel + Gemcitabine Dose Level -2 | Part 1: Gemcitabine + Cabazitaxel Dose Level 0 | Total |
|---|---|---|---|---|---|
| Stage I | 0 | 0 | 0 | 0 | 0 |
| Stage II | 0 | 1 | 0 | 0 | 1 |
| Stage III | 0 | 3 | 0 | 1 | 4 |
| Stage IV | 5 | 0 | 0 | 2 | 7 |
| Unknown | 0 | 1 | 3 | 3 | 7 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2009, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabazitaxel · Gemcitabine